Scholar Rock Earnings Call - SCHOLAR ROCK HOLDING CORP

Explicit Guidance:

• Revenue: No specific forward-looking revenue or earnings figures provided; however, management expects "steady and consistent growth in revenues" over time with a "healthy growth story" quarter-on-quarter, noting that initial infusions are projected to occur in 2027 due to 60–90 day reimbursement timelines.
• Cash & Liquidity: Projected cash position to increase by $205 million from the sale of a priority review voucher upon transaction closing; access to an additional $150 million under existing debt facility following FDA approval.
• Capex/Opex: No specific capex or opex ranges provided; commitment to maintain disciplined spend while funding global launches and R&D.
• Share Count/Dividends/Buybacks: Explicitly stated "no need for an equity offering at this time" to fund strategic priorities.

Business-Segment Outlook:

• Geographies:
  • U.S.: Launch commenced mid-September; majority of enrolled patients expected to begin infusions in 2027. Anticipate steady progress on payer approvals and policy alignment.
  • Europe: CHMP opinion expected in the first half of 2027; initial launch in Germany later in 2027, followed by other key countries.
  • Japan: Application under priority review (9-month cycle); anticipated launch near year-end 2027.
• Patient Populations: Current enrollment includes a mix of children and adults across the full spectrum of disease trajectories (improving, plateaued, declining). Treatment-naive patients currently outnumber those transitioning from clinical trials/EAPs.
• Pipeline/Indications:
  • FSHD (Phase 2 FORGE study): Dosing commenced in Q3 2026; enrollment ongoing.
  • SMA Infants (<2 years): Phase 2 OPAL study evaluating subcutaneous formulation in infants/toddlers; enrollment robust.
  • Subcutaneous Formulation (Life-cycle): Regulatory engagements initiated to establish development path; aims to provide caregiver-administered optionality and potentially expand the adult market.
  • SRK439 (Next-gen myostatin inhibitor): Phase 1 Healthy Volunteer Study dosing progressing; top-line data expected by year-end 2026, with sharing planned for early 2027.

Market and Competitive Outlook:

• Demand Trends: Demand is described as "steady and consistent" on a weekly basis, outpacing reimbursement capabilities. Prescriber engagement reached 95% of top 140 SMA treatment centers within six weeks.
• Access & Payer Environment: Anticipate a transition from current 60–90+ day prescription-to-infusion timelines to "more manageable" speeds as J-code is implemented (April 1, 2027) and payer policies stabilize. Payer policies are expected to align with the broad label (no age, type, or ambulatory restrictions) over the next six months.
• Competitive Dynamics: Management views high-dose Spinraza as a "net positive" for expanding the overall SMN2 market. Zolgensma impact remains neutral; iAssembled is the sole option for addressing the muscle component.
• Market Size: Potential to serve an estimated 6,600 patients in the U.S. and up to 35,000 patients globally currently on SMN-targeted therapy.

Macro / Industry Outlook:

• Regulatory Landscape: Anticipate priority review standards in Japan (approx. 9-month cycle). Expectation that U.S. approval will facilitate early access programs and data sharing in international partner markets (Eastern Europe, etc.) prior to local approval.
• Safety/Label: No impact observed on demand or prescribing patterns regarding the bone fracture warning; management views this as standard industry experience.

Strategic Initiatives:

• Commercial Expansion: Building a 50-country operating platform; expanding U.S. coverage to include centers outside the top 140.
• M&A/Asset Monetization: Definitive agreement to sell priority review voucher for $205 million to strengthen balance sheet for global commercial and R&D initiatives.
• Supply Chain: Validated alternate fill-finish facility for European submission; preparing for increased global demand for iAssembled and pipeline assets.
• Lifecycle Management: Advancing subcutaneous formulation development and the OPAL study to expand treatable population to the youngest SMA patients.

Risks and Headwinds to Outlook:

• Reimbursement Delays: Initial "speed bumps" in patient access (60–90+ days from prescription to infusion) due to lack of specific J-codes (until April 1, 2027), formulary approvals, and payer policy establishment.
• Access Complexity: Prior authorizations, denials, and hospital formulary add-ons are expected to persist, though manageable with established support programs.
• Execution Risk: Success of global launches in Europe and Japan dependent on regulatory timelines (CHMP opinion, PMDA review) and subsequent pricing/reimbursement negotiations.

Management Tone on the Future:

• Confidence: High confidence and urgency in execution. Management describes the launch progress as "exceeding expectations" and reinforces the view that patient access is "a matter of when and not if."
• Steady Growth: Explicitly rejects a "bolus" sales pattern, predicting a steady, consistent ramp as payer hurdles are cleared.
• Financial Discipline: Reiterated commitment to operating without dilutive equity offerings in the near term, citing strong liquidity.
• Strategic Vision: Describes the company as transitioning from a clinical-stage biotech to a "global biotech powerhouse" with a "world-leading platform."

Miscellaneous:

• J-Code Implementation: Filed J-code application for iAssembled to be effective April 1, 2027, to reduce reimbursement timelines.
• Patient Support: 98% of patients utilizing Scholar Rock Supports for navigation, highlighting the critical role of the support program in managing complex payer landscapes.
• Data Points: 93% retention rate observed in prior trial patients; 95% engagement with top 140 treatment centers achieved in 6 weeks.